Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer

NCT01940276 ↗

Phase 2 Completed 100 enrolled Duke University

NaSingle-groupOpen-labelTreatment

Summary

The primary goal is to prospectively estimate the median radiographic PFS of African American and Caucasian men with mCRPC to abiraterone acetate and prednisone.

Timeline

Start: 2013-10
Primary completion: 2019-10-08
Completion: 2019-10-08

Publications

Piwarski SA, Howard LE, Paul MA, Bachelder N, LaCroix B, Clayton A, Allen D, Kephart J, Armstrong AJ, Patierno SR, George DJ, Hyslop T, Freedman JA. Genetic ancestry-concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration-resistant prostate cancer. Cancer. 2026 Jun 1;132(11):e70371. doi: 10.1002/cncr.70371.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abiraterone acetate	Small molecule	1000 mg	Oral
Background	Prednisone	Other / unclassified	5 mg	—

Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications